Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Gynecologic Oncology

RSS  

Articles

  • Panitumumab-FOLFIRI: Effective Second-line Treatment for Metastatic Colorectal Cancer

    A previously reported, industry-sponsored phase 3 trial showed improvements in progression-free survival, objective response, and a non-significant trend toward increased overall survival with panitumumab-FOLFIRI vs FOLFIRI alone for second-line wild-type KRAS metastatic colorectal cancer.
  • Choosing Myeloma Maintenance Therapy: Patient Choice

    In a survey of consecutive myeloma patients from the Mayo Clinic on hypothetical constructs with varying expectations regarding overall survival benefit, toxicity, and financial burden, it was found that the majority of patients would not choose maintenance if toxicity was more than just mild and overall survival benefit was less than 1 year.
  • Contralateral Mastectomy Improves 20-year Survival for BRCA-positive Breast Cancer Patients

    For patients with BRCA-associated breast cancer, it had been previously demonstrated that a second breast cancer occurs in approximately one-third of patients by 15 years after diagnosis, and that this risk was reduced significantly by contralateral mastectomy.
  • Addition of Bevacizumab for Newly Diagnosed Glioblastoma

    In a multicenter, randomized, double-blind, placebo-controlled clinical trial of bevacizumab added to standard temozolomide and radiation therapy for patients with glioblastoma multiforme, progression-free survival but not overall survival was enhanced.
  • Primary Tumor Resection in Patients Presenting with Metastatic Colorectal Cancer

    In a well-controlled retrospective analysis of patients who presented with metastatic colorectal cancer, primary tumor resection was associated with improved overall survival.
  • Adding to Survival ... Again: Cervical Cancer

    Bevacizumab added to chemotherapy, particularly paclitaxel and cisplatin, was efficacious in all response outcomes (objective response, progression-free survival, and overall survival) without diminution in quality of life or unacceptable toxicity.
  • Cancer-reducing Effect of OCPs in BRCA1/BRCA2 Carriers: Do They Work?

    The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population. Oral contraceptive pill use is inversely associated with ovarian cancer risk. However, it is also associated with a modest, but not statistically significant, increased risk for breast cancer. The analysis was unable to provide conclusive recommendations as to their use as preventive measures given these and other unmeasured risks. However, oral contraceptive pills appear safe for contraception in this population.
  • Should You Advise Your Patients to Eat Peanuts During Pregnancy?

    Synopsis: In this study, women without allergies who consumed peanuts or tree nuts five times or more per month around the time of pregnancy compared to less than one time per month had reduced odds of having children with peanut or tree nut allergies.
  • First Trimester Anatomy

    A meta-analysis of 19 studies involving first trimester screening for fetal anomalies has shown that a majority of major structural abnormalities can be diagnosed between 11 and 14 weeks and that even cardiac abnormalities can be identified with ultrasound with reasonable efficiency.
  • Emergency Contraception

    We now have three options for emergency contraception the copper IUD, oral ulipristal acetate, and oral levonorgestrel. One of the most important considerations in using emergency contraception is the initiation of ongoing regular contraception. The special feature will discuss the opportunities and considerations for use of these three different methods of postcoital contraception.